Research Article

Fasting insulin, insulin resistance, and risk of cardiovascular or all-cause mortality in non-diabetic adults: a meta-analysis

Xiaohong Zhang¹,*, Jun Li²,*, Shuiping Zheng¹, Qiuyun Luo¹, Chunmei Zhou¹ and Chaoyang Wang¹

¹Department of Cardiovascular Diseases, Jingmen Traditional Chinese Medical Hospital (Jingmen Shihua Hospital), Jingmen 448000, China; ²Department of Endocrinology, Jingmen Traditional Chinese Medical Hospital (Jingmen Shihua Hospital), Jingmen 448000, China

Correspondence: Chaoyang Wang (wangchaoyangjm@126.com)

Studies on elevated fasting insulin or insulin resistance (IR) and cardiovascular or all-cause mortality risk in non-diabetic individuals have yielded conflicting results. This meta-analysis aimed to evaluate the association of elevated fasting insulin levels or IR as defined by homeostasis model assessment of IR (HOMA-IR) with cardiovascular or all-cause mortality in non-diabetic adults. We searched for relevant studies in PubMed and Emabse databases until November 2016. Only prospective observational studies investigating the association of elevated fasting insulin levels or HOMA-IR with cardiovascular or all-cause mortality risk in non-diabetic adults were included. Risk ratio (RR) with its 95% confidence intervals (CIs) was pooled for the highest compared with the lowest category of fasting insulin levels or HOMA-IR. Seven articles involving 26976 non-diabetic adults were included. The pooled, adjusted RR of all-cause mortality comparing the highest with the lowest category was 1.13 (95% CI: 1.00–1.27; P=0.058) for fasting insulin levels and 1.34 (95% CI: 1.11–1.62; P=0.002) for HOMA-IR, respectively. When comparing the highest with the lowest category, the pooled adjusted RR of cardiovascular mortality was 2.11 (95% CI: 1.01–4.41; P=0.048) for HOMA-IR in two studies and 1.40 (95% CI: 0.49–3.96; P=0.526) for fasting insulin levels in one study. IR as measured by HOMA-IR but not fasting insulin appears to be independently associated with greater risk of cardiovascular or all-cause mortality in non-diabetic adults. However, the association of fasting insulin and HOMA-IR with cardiovascular mortality may be unreliable due to the small number of articles included.

Introduction

Insulin resistance (IR) is defined as the inability of insulin to increase cellular glucose uptake and utilization, leading to compensatory hyperinsulinemia [1]. IR can be measured by a hyperinsulinemic-euglycemic clamp, indirect estimates of homeostasis model assessment (HOMA) or calculated using dynamic oral glucose tolerance test. The hyperinsulinemic-euglycemic clamp method is recognized as the gold standard for estimating IR [2]. However, this procedure is not suitable for large population-based studies due to its invasive and time-consuming nature. HOMA-IR estimating IR from fasting glucose and insulin levels is particularly appropriate for large epidemiological studies [3]. There is good correlation between values of IR obtained by HOMA-IR and the hyperinsulinemic-euglycemic clamp procedure [4].

IR promotes the development of atherosclerosis through increasing insulin and glucose levels. Hyperinsulinemia and hyperglycemia can exert direct atherogenic effect on the vessel wall [5]. IR also reduces the ability of adipose tissue to store proatherogenic lipids and produces a
variety of proinflammatory mediators from the adipose tissue [6]. All these factors thus contribute to atherosclerosis.

Hyperinsulinemia or HOMA-IR has been considered as a surrogate measure of IR [7]. Several prospective studies [8-10] but not all [11-15] have shown that hyperinsulinemia or HOMA-IR was associated with greater risk of cardiovascular or all-cause mortality. A previous meta-analysis [16] suggested that hyperinsulinemia was independently associated with an exacerbated risk of cardiovascular mortality in non-diabetic individuals. Another meta-analysis [17] indicated that elevated fasting insulin and HOMA-IR were associated with higher risk of cardiovascular disease in non-diabetic individuals. However, these two well-designed meta-analyses did not evaluate the association of fasting insulin or HOMA-IR with all-cause mortality risk.

This meta-analysis aimed to evaluate the association of elevated fasting insulin/HOMA-IR with cardiovascular or all-cause mortality risk in non-diabetic adults on the basis of prospective observational studies.

Materials and methods

Search strategy

The present study was performed in accordance with the checklist of Meta-analysis of Observational Studies in Epidemiology reporting guidelines [18]. Two authors (X. Zhang and J. Li) independently made the literature search on PubMed and Embase databases until November 2016 without language restrictions. The following keywords in various combinations were used: ‘insulin’ OR ‘hyperinsulinemia’ OR ‘insulin resistance’ OR ‘homeostasis model assessment’ OR ‘HOMA-IR’ AND ‘mortality’ OR ‘death’ AND ‘prospective’ OR ‘longitudinal’ OR ‘follow-up’. We also manually searched the reference list of the included studies to identify any additional eligible articles.

Study selection

The following inclusion criteria were applied: (i) prospective observational studies enrolling non-diabetic adults; (ii) fasting insulin levels or IR measured by HOMA as exposure; and (iii) reported multiple adjusted risk ratio (RR) or hazard ratio (HR) with 95% confidence interval (CI) of cardiovascular or all-cause mortality comparing the highest with the lowest category of fasting insulin or HOMA-IR. Studies were excluded if: (i) enrollment of patients with diabetes at baseline; (ii) unavailable fasting insulin or HOMA-IR data; (iii) reported risk estimate by continuous value of fasting insulin levels or HOMA-IR. Data from the cross-sectional, case-control, or retrospective studies, reviews, and conference abstract were also excluded.

Data extraction and quality assessment

Two authors (X. Zhang and J. Li) independently extracted the data and assessed the study quality from the included studies. Any disagreements in these phases were resolved by consensus. The extracted data included: first author’s surname, publication year, country of origin, study design, number of participants, proportion of women, age at baseline, fasting time, methods of insulin assay, formula of HOMA-IR calculation, cut-off value of fasting insulin or HOMA-IR comparison, total number of death events, fully adjusted risk estimate, duration of follow-up, and adjustment of variables. Study quality was assessed by a 9-star Newcastle–Ottawa Scale (NOS) for cohort studies1. NOS stars of 7 or more were considered as high-quality studies.

Statistical analyses

All statistical analyses were performed using STATA software (version 12.0, Stata, College Station, TX, U.S.A.). HR were assumed to approximate the same measure of RR. We considered the presence of significant heterogeneity across studies according to P<0.1 for Cochran Q-statistic and quantitated by the I² tests with its value ≥50%. A random-effects model was chosen in the presence of significant heterogeneity; otherwise, a fixed-effect model was selected1. Publication bias was planned by an assessment of the Begg’s test [19] and Egger’s test [20] if more than ten articles were retrieved. Sensitivity analyses were conducted by removing a single study from the overall analysis at each turn.

1 Wells, G., Shea, B., O’Connell, D., Peterson, J., Welch, V., Losos, M. et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinicalepidemiology/oxford.asp (Accessed 3 September 2017).

2 Higgins, J.P.T. and Green, S.E. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011], The Cochrane Collaboration http://training.cochrane.org/handbook (Accessed 3 September 2017).
Table 1: Baseline characteristics of the selected studies

| Study (year)       | Study region      | Design                              | Subjects (% female) | Age (years) | Fasting times | Insulin assay | Insulin comparison | IR definition | HOMA-IR comparison | RR/HR (95% CI) | Follow-up (years) | Adjusted for variables |
|--------------------|-------------------|-------------------------------------|---------------------|-------------|---------------|---------------|-------------------|---------------|--------------------|----------------|------------------|-----------------------|
| Lakka et al. (2000) [11] | Finland           | Prospective population-based study  | 1521 (0)            | 42–60       | 12 h          | RIA           | Quintile (pmol/L) 4 compared with 1; ≥90 compared with <52 | –            | –                  | CV death: 45; 1.4 (0.5–4.0) | 9.5              | Age, examination years, smoking, alcohol, HDL, TG, BMI, SBP, DBP, WC, blood leukocyte count, apolipoprotein B, fibrinogen, and maximal oxygen uptake |
| Hedblad et al. (2002) [8] | Sweden            | Prospective cohort study            | 4748 (60.8)         | 46–68       | Overnight     | RIA           | Fasting insulin (μU/ml) × glucose (mmol/l)/ 22.5 | 1.80 for women and 2.12 for men | Total deaths: 93; 1.62 (1.03–2.55) | 5               | Age, sex, SBP, hypertension, HDL, TG, glucose, WC, smoking, and leisure-time PA |
| Nilsson et al. (2003) [12] | Sweden            | Prospective cohort                 | 6074 (0)            | 25–63       | Not reported  | RIA           | Tenth decile compared with others; 21–140 compared with 1–20 mU/l | –            | –                  | Total deaths: 1012; 1.17 (0.96–1.41) | 19              | Age, SBP, TC, TG, smoking, fasting glucose, and BMI |
| Ausk et al. (2010) [9] | U.S.A.            | Prospective cohort study            | 5511 (NP)           | ≥20         | 10–16 h for morning test or 6 h for other tests | RIA           | Quintile (pmol/l) 4 compared with 1; >11.5 compared with ≤6.15 | Fasting insulin (μU/ml) × glucose (mmol/l)/ 22.5 | Quintile 4 compared with quintile 1; >2.8 compared with ≤4 | Total deaths: 643; 1.64 (1.1–2.5) IR; 1.48 (0.9–2.2) insulin; CV deaths: 237; 3.2 (1.7–5.9) IR | 8.5              | Age, sex, BMI, waist-to-hp ratio, race/ethnicity, smoking, alcohol, PA, SBP, DBP, TC, HDL, TG, education, and CRP |
| de Boer et al. (2012) [13] | U.S.A.            | Prospective, community-based cohort | 3138 (61)           | 72 ± 5.0    | Not reported  | RIA           | Quintile (IU/ml) 4 compared with 1; >18 compared with <10 | –            | –                  | Total deaths: 1810; 1.05 (0.89–1.25) | 14.7             | Age, sex, race, study site, prevalent CVD, smoking, lipid-lowering medication, LDL, PA, WC, SBP, DBP, antihypertensive drugs, HDL, triglyceride, CRP, and eGFR |
| Kim et al. (2013) [10] | Korea             | Prospective community-based study   | 743 (57.5)          | 76.4 ± 9.3  | ≥12 h         | RIA           | –                | Fasting glucose (mg/l) × insulin (μU/ml)/405 | Quintile 5 compared with quintile 3; >1.5 compared with 0.85–1.07 | Total deaths: 168; 2.01 (1.06–3.90); | 5.2              | Age, TC, hemoglobin, eGFR, proteinuria, CRP, and DBP |
| Kim et al. (2015) [15] | U.S.A.            | Prospective study                  | 5241 (56.2)         | 58.9 ± 13.9 | ≥8 h          | RIA and immunoenzymometric assay | –                | Fasting insulin (μU/ml) × glucose (mmol/l)/ 22.5 | Quintile 4 compared with quintile 1; >2.67 compared with ≤1.29 | Total deaths: 724; 1.1 (0.9–1.5); CV deaths: 316; 1.5 (1.0–2.2) | 6.6              | Age, gender, race/ethnicity, smoking, survey cycle, BMI, LDL, HDL, and SBP |

Abbreviations: BMI, body mass index; CBD, cerebrovascular disease; CHD, coronary heart disease; CRP, C-reactive protein; CV, cardiovascular; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NP, not provided; PA, physical activity; PAD, peripheral vascular disease; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; WC, waist circumference.
Figure 1. Flow chart of the study selection process

Results

Search results and study characteristics

Figure 1 depicts the detailed process of the study selection. A total of seven studies [8-13,15] were included in the final meta-analysis. Table 1 summarizes the baseline characteristics of the included studies. Seven articles involving 26976 non-diabetic individuals were identified. Sample sizes ranged from 743 to 6074 in the individual studies. Three articles [9,13,15] were conducted in the U.S.A., three [8,11,12] in Europe, and one [10] in Korea. Two articles [11,12] consisted of men only. Three articles [11-13] only reported fasting insulin levels, three articles [8,10,15] reported HOMA-IR only, and one article [9] simultaneously reported fasting insulin and HOMA-IR. The follow-up duration ranged from 5.0 to 19.0 years. Using the NOS scale, the overall NOS in each study ranged from 6 to 8 stars (Supplementary Table S1).

Association of fasting insulin and HOMA-IR with all-cause mortality

Three studies [9,12,13] reported the association of fasting insulin levels with all-cause mortality risk. As shown in Figure 2(A), the pooled RR of all-cause mortality was 1.13 (95% CI: 1.00–1.27; $P=0.058$) for the highest compared with lowest category of fasting insulin levels in a fixed-effect model. There was no evidence of heterogeneity across studies ($I^2=10.7\%$, $P=0.326$). Sensitivity analyses indicated that there were slight changes in magnitude of the combined risk estimate when any single study was excluded.

Four studies [8-10,15] reported the association of HOMA-IR with all-cause mortality risk. As shown in Figure 2(B), the pooled RR of all-cause mortality was 1.34 (95% CI: 1.11–1.62; $P=0.002$) for the highest compared with lowest category of HOMA-IR in a fixed-effect model, with no evidence of significant heterogeneity ($I^2=44.3\%$, $P=0.146$). Sensitivity analysis by removing individual study at a time showed that there were slight changes in magnitude of the pooled risk summary (results not shown).

Association of fasting insulin and HOMA-IR with cardiovascular mortality

As shown in Figure 3, the pooled RR of cardiovascular mortality for the highest compared with lowest category was 1.40 (95% CI: 0.49–3.96; $P=0.526$) for fasting insulin levels in one study [11] and 2.11 (95% CI: 1.01–4.41; $P=0.048$)
Figure 2. Forest plots showing pooled RR and 95% CI of all-cause mortality for the highest compared with lowest category of fasting insulin level and IR.

Figure 3. Forest plots showing pooled RR and 95% CI of cardiovascular mortality for the highest compared with lowest category of fasting insulin level and IR.

© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
for HOMA-IR in two studies [9,15] in a random-effect model. There was evidence of significant heterogeneity between two studies ($I^2 = 75.4\%$, $P=0.044$).

**Subgroup analyses and publication bias**
As for the small number of studies included, we did not conduct subgroup analysis and publication bias because statistical tests for these analyses may be potentially unreliable.

**Discussion**
This is the first meta-analysis to investigate the association of fasting insulin levels and IR with all-cause mortality risk in non-diabetic adults. Our meta-analyses suggested that IR as measured by HOMA-IR appeared to be independently associated with greater risk of cardiovascular and all-cause mortality. When quantitated as the highest compared with lowest category, individuals with the highest HOMA-IR had a 111 and 34% greater risk of cardiovascular and all-cause mortality, respectively.

IR is considered a better biomarker than insulin or glucose alone because it incorporates both the biomarkers. Our meta-analysis indicated that HOMA was associated with greater risk of all-cause mortality in adults without diabetes; however, the predictive role of elevated fasting insulin itself in this process was not statistically significant. These findings should be taken with caution because the result was established on an indirect comparison. We could not directly compare the magnitude of the association of HOMA-IR and fasting insulin because most studies failed to report results simultaneously.

A study-level meta-analysis [16] of prospective data from 11 DECODE study populations suggested that both fasting insulin and HOMA-IR were independently associated with cardiovascular mortality in non-diabetic men and women. However, this well-designed meta-analysis did not evaluate the effects of fasting insulin and HOMA-IR on all-cause mortality risk. Our meta-analysis particularly focussed on the association of fasting insulin and HOMA-IR with all-cause mortality risk. We found that only IR as measured by HOMA-IR was associated with higher risk of all-cause mortality in non-diabetic adults.

Mechanisms underlying IR on the development of cardiovascular and all-cause mortality are considered to be through the direct atherogenic action of insulin on vessel wall [5,6] and/or indirect through obesity, blood pressure, lipids and metabolic homeostasis [21]. IR is the core metabolic abnormality in metabolic syndrome. Nevertheless, metabolic syndrome was an important risk factor for all-cause mortality [22]. Moreover, IR has been associated with type 2 diabetes [23], hypertension [19], cardiovascular disease [20], and a variety of cancers [24,25]. All above-mentioned diseases contribute to the risk of premature mortality.

This meta-analysis has several limitations. First, HOMA-IR strongly reflects hepatic IR than the total effect of systemic IR [4] and we only included studies using the HOMA-IR index to estimate IR. Second, analyses related only to single baseline value of fasting insulin and HOMA-IR; therefore, misclassification of individuals in each category could not be excluded. Time average insulin and HOMA-IR analysis in future studies will further confirm the observed association. Third, we could not determine the optimal cut-off value of HOMA-IR due to different formulas of HOMA-IR used. Finally, our meta-analysis was a study-level meta-analysis not a individual-level meta-analysis, therefore, we cannot control some potential confounders. Lack of adjustment for dietary patterns and degrees of physical activity, prediabetes, obesity, physical activity, renal function, or medications may lead to slight overestimation of the risk estimates.

In summary, this meta-analysis suggests that IR as measured by HOMA-IR appears to be independently associated with greater risk of all-cause mortality in non-diabetic adults. Early ascertaining of IR may help to improve all-cause mortality risk stratification amongst the non-diabetic adults. However, the association of fasting insulin and HOMA-IR with cardiovascular mortality may be unreliable due to the small number of articles included. More well-designed prospective studies are needed to confirm the findings of this meta-analysis.

**Competing interests**
The authors declare that there are no competing interests associated with the manuscript.

**Author contribution**
X.Z. and J.L. made the literature research, extracted data, and performed the statistical analysis. S.Z. and Q.L. evaluated the quality of the included study. C.Z. drafted the manuscript. C.W. designed the present study, interpreted the results, and revised the manuscript. All the listed authors approved the final manuscript.
Funding
The authors declare that there are no sources of funding to be acknowledged.

Abbreviations
CI, confidence interval; HOMA, homeostasis model assessment; HOMA-IR, homeostasis model assessment of insulin resistance; HR, hazard ratio; IR, insulin resistance; NOS, Newcastle–Ottawa Scale; RR, risk ratio.

References
1. Shanik, M.H., Xu, Y., Skrha, J., Dankner, R., Zick, Y. and Roth, J. (2008) Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care 31 (Suppl. 2), S262–S268
2. Borai, A., Livingstone, C., Kaddam, I. and Ferns, G. (2011) Selection of the appropriate method for the assessment of insulin resistance. BMC Med. Res. Methodol. 11, 158
3. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. and Turner, R.C. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419
4. Wallace, T.M., Levy, J.C. and Matthews, D.R. (2004) Use and abuse of HOMA modeling. Diabetes Care 27, 1487–1495
5. Bornfeldt, K.E. and Tabas, I. (2011) Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 14, 575–585
6. Raghavan, V.A. (2012) Insulin resistance and atherosclerosis. Diabetologia 55, 1160–1168
7. Lakka, H.M., Lakka, T.A., Tuomilehto, J., Sivenius, J. and Salonen, J.T. (2000) Hyperinsulinemia and the risk of cardiovascular death and acute coronary and cerebrovascular events in men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Arch. Intern. Med. 160, 1160–1168
8. Nilsson, P., Nilsson, J.A., Hedblad, B., Eriksson, K.F. and Berglund, G. (2003) Hyperinsulinemia as long-term predictor of death and ischaemic heart disease in nondiabetic men: the Malmo Preventive Project. J. Intern. Med. 253, 136–145
9. de Boer, I.H., Katz, R., Chonchol, M.B., Fried, L.F., Ik, J.H., Kestenbaum, B. et al. (2012) Insulin resistance, cystatin C, and mortality among older adults. Diabetes Care 35, 1355–1360
10. Welsh, P., Preiss, D., Lloyd, S.M., de Craen, A., Jukema, J.W., Westendorp, R.G. et al. (2014) Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up. Diabetologia 57, 2513–2520
11. Kim, K.S., Lee, Y.M., Lee, I.K., Kim, D.J., Jacobs, Jr, D.R. and Lee, N. (2010) Paradoxical associations of insulin resistance with lower glomerular filtration rate and all-cause mortality in the elderly: PROSPER long-term follow-up. Diabetologia 53, R260–R268
12. Wu, S.H., Liu, Z. and Ho, S.C. (2010) Metabolic syndrome and all-cause mortality: a meta-analysis of prospective cohort studies. Eur. J. Epidemiol. 25, 375–384
13. Greenfield, J.R. and Campbell, L.V. (2006) Relationship between inflammation, insulin resistance and type 2 diabetes: ‘cause or effect’. Curr. Diabetes Rev. 2, 195–211
14. Inoue, M. and Tsugane, S. (2012) Insulin resistance and cancer: epidemiological evidence. Endocr. Relat. Cancer 19, F1–F8
15. Djouge, S., Dwabo Kamdje, A.H., Vecchio, L., Kipanyula, M.J., Farahna, M., Aldebas, Y. et al. (2013) Insulin resistance and cancer: the role of insulin and IGFs. Endocr. Relat. Cancer 20, R1–R17
16. Laakso, M. (2015) Is insulin resistance a feature of or a primary risk factor for cardiovascular disease? A meta-analysis of data from eleven prospective studies. Diabetologia 47, 1245–1256
17. Gast, K.B., Tijkerdema, N., Stijnen, T., Smit, J.W. and Dekkers, O.M. (2012) Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis. PLoS ONE 7, e52036
18. Stroup, D.F., Berlin, J.A., Morton, S.C., Olkin, I., Williamson, G.D., Rennie, D. et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283, 2008–2012
19. Wang, F., Han, L. and Hu, D. (2016) Fasting insulin, insulin resistance and risk of hypertension in the general population: a meta-analysis. Clin. Chim. Acta 464, 57–63
20. Lakso, M. (2015) Is insulin resistance a feature of or a primary risk factor for cardiovascular disease? Curr. Diab. Rep. 15, 105
21. Ginsberg, H.N. (2000) Insulin resistance and cardiovascular disease. J. Clin. Invest. 106, 453–458
22. Wu, S.H., Liu, Z. and Ho, S.C. (2010) Metabolic syndrome and all-cause mortality: a meta-analysis of prospective cohort studies. Eur. J. Epidemiol. 25, 375–384
23. Greenfield, J.R. and Campbell, L.V. (2006) Relationship between inflammation, insulin resistance and type 2 diabetes: ‘cause or effect’. Curr. Diabetes Rev. 2, 195–211
24. Inoue, M. and Tsugane, S. (2012) Insulin resistance and cancer: epidemiological evidence. Endocr. Relat. Cancer 19, F1–F8
25. Djojoe, S., Dwabo Kamdje, A.H., Vecchio, L., Kipanyula, M.J., Farahna, M., Aldebas, Y. et al. (2013) Insulin resistance and cancer: the role of insulin and IGFs. Endocr. Relat. Cancer 20, R1–R17